Galapagos (GLPG.AS) Stock Price

Galapagos Price

Euronext·CLOSED
22.32EUR+6.33 (+33.05 %)
Market closed

Revenue has compounded at 19.9% per year over the past 19 years to 1.11 B EUR. Earnings per share have grown at 25.0% per year over the last 16 years. Galapagos's net margin stands at 28.9%, up from -25.9% several years earlier. Analysts set a median price target of 28.46 EUR, implying 27.5% above the current price. Of 18 analysts, 3 rate the stock a buy — an overall Sell consensus. The stock trades about 134% above its 52-week low.

Galapagos stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Galapagos over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Galapagos stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Galapagos's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Galapagos Stock Price History
DateGalapagos Price
8/6/202622.32 EUR
8/4/202615.99 EUR
8/3/202615.99 EUR
7/30/202615.99 EUR
7/17/202615.99 EUR
7/8/202615.99 EUR
7/7/202616.03 EUR
7/6/202615.75 EUR
7/3/202616.05 EUR
7/2/202615.72 EUR
7/1/202615.51 EUR
6/30/202615.64 EUR
6/29/202615.33 EUR
6/26/202615.33 EUR
6/25/202615.08 EUR
6/24/202615.15 EUR
6/23/202615.13 EUR
6/22/202614.89 EUR
6/19/202614.68 EUR
6/18/202614.67 EUR
6/17/202614.77 EUR
6/16/202614.39 EUR
6/15/202614.96 EUR
6/12/202614.88 EUR
6/11/202614.82 EUR
6/10/202614.67 EUR
6/9/20269.54 EUR
6/8/20269.54 EUR
6/5/20269.54 EUR
6/4/20269.54 EUR
6/3/20269.54 EUR
6/2/20269.54 EUR
6/1/20269.54 EUR
5/29/20269.54 EUR
5/28/20269.54 EUR
5/27/20269.54 EUR
5/26/20269.54 EUR
5/25/20269.54 EUR
5/22/20269.54 EUR
5/21/20269.54 EUR
5/20/20269.54 EUR
5/19/20269.54 EUR
5/18/20269.54 EUR
5/15/20269.54 EUR
5/14/20269.54 EUR
5/13/20269.54 EUR
5/12/20269.54 EUR
5/11/20269.54 EUR
5/8/20269.54 EUR
5/7/20269.54 EUR
5/6/20269.54 EUR
5/5/20269.54 EUR
5/4/20269.54 EUR
4/30/20269.54 EUR
4/29/20269.54 EUR
4/28/20269.54 EUR
4/27/20269.54 EUR
4/24/20269.54 EUR
4/23/20269.54 EUR
4/22/20269.54 EUR
4/21/20269.54 EUR
4/20/20269.54 EUR
4/17/20269.54 EUR
4/16/20269.54 EUR
4/15/20269.54 EUR
4/14/20269.54 EUR
4/13/20269.54 EUR
4/10/20269.54 EUR
4/9/20269.54 EUR
4/8/20269.54 EUR
4/7/20269.54 EUR
4/2/20269.54 EUR
4/1/20269.54 EUR
3/31/20269.54 EUR
3/30/20269.54 EUR
3/27/20269.54 EUR
3/26/20269.54 EUR
3/25/20269.54 EUR
3/24/20269.54 EUR
3/23/20269.54 EUR
3/20/20269.54 EUR
3/19/20269.54 EUR
3/18/20269.54 EUR
3/17/20269.54 EUR
3/16/20269.54 EUR
3/13/20269.54 EUR
3/12/20269.54 EUR
3/11/20269.54 EUR
3/10/20269.54 EUR
3/9/20269.54 EUR
3/6/20269.54 EUR
3/5/20269.54 EUR
3/4/20269.54 EUR
3/3/20269.54 EUR
3/2/20269.54 EUR
2/27/20269.54 EUR
2/26/20269.54 EUR
2/25/20269.54 EUR
2/24/20269.54 EUR
2/23/20269.54 EUR
2/20/20269.54 EUR
2/19/20269.54 EUR
2/18/20269.54 EUR
2/17/20269.54 EUR
2/16/20269.54 EUR
2/13/20269.54 EUR
2/12/20269.54 EUR
2/11/20269.54 EUR
2/10/20269.54 EUR
2/9/20269.54 EUR
2/6/20269.54 EUR
2/5/20269.54 EUR
2/4/20269.54 EUR
2/3/20269.54 EUR
2/2/20269.54 EUR
1/30/20269.54 EUR
1/29/20269.54 EUR
1/28/20269.54 EUR
1/27/20269.54 EUR
1/26/20269.54 EUR
1/23/20269.54 EUR
1/22/20269.54 EUR
1/21/20269.54 EUR
1/20/20269.54 EUR
1/19/20269.54 EUR
1/16/20269.54 EUR
1/15/20269.54 EUR
1/14/20269.54 EUR
1/13/20269.54 EUR
1/12/20269.54 EUR
1/9/20269.54 EUR
1/8/20269.54 EUR
1/7/20269.54 EUR
1/6/20269.54 EUR
1/5/20269.54 EUR
1/2/20269.54 EUR
12/31/20259.54 EUR
12/30/20259.54 EUR
12/29/20259.54 EUR
12/24/20259.54 EUR
12/23/20259.54 EUR
12/22/20259.54 EUR
12/19/20259.54 EUR
12/18/20259.54 EUR
12/17/20259.54 EUR
12/16/20259.54 EUR
12/15/20259.54 EUR
12/12/20259.54 EUR
12/11/20259.54 EUR
12/10/20259.54 EUR
12/9/20259.54 EUR
12/8/20259.54 EUR
12/5/20259.54 EUR
12/4/20259.54 EUR
12/3/20259.54 EUR
12/2/20259.54 EUR
12/1/20259.54 EUR
11/28/20259.54 EUR
11/27/20259.54 EUR
11/26/20259.54 EUR
11/25/20259.54 EUR
11/24/20259.54 EUR
11/21/20259.54 EUR
11/20/20259.54 EUR
11/19/20259.54 EUR
11/18/20259.54 EUR
11/17/20259.54 EUR
11/14/20259.54 EUR
11/13/20259.54 EUR
11/12/20259.54 EUR
11/11/20259.54 EUR
11/10/20259.54 EUR
11/7/20259.54 EUR
11/6/20259.54 EUR
11/5/20259.54 EUR
11/4/20259.54 EUR
11/3/20259.54 EUR
10/31/20259.54 EUR
10/30/20259.54 EUR
10/29/20259.54 EUR
10/28/20259.54 EUR
10/27/20259.54 EUR
10/24/20259.54 EUR
10/23/20259.54 EUR
10/22/20259.54 EUR
10/21/20259.54 EUR
10/20/20259.54 EUR
10/17/20259.54 EUR
10/16/20259.54 EUR
10/15/20259.54 EUR
10/14/20259.54 EUR
10/13/20259.54 EUR
10/10/20259.54 EUR
10/9/20259.54 EUR
10/8/20259.54 EUR
10/7/20259.54 EUR
10/6/20259.54 EUR
10/3/20259.54 EUR
10/2/20259.54 EUR
10/1/20259.54 EUR
9/30/20259.54 EUR
9/29/20259.54 EUR
9/26/20259.54 EUR
9/25/20259.54 EUR
9/24/20259.54 EUR
9/23/20259.54 EUR
9/22/20259.54 EUR
9/19/20259.54 EUR
9/18/20259.54 EUR
9/17/20259.54 EUR
9/16/20259.54 EUR
9/15/20259.54 EUR
9/12/20259.54 EUR
9/11/20259.54 EUR
9/10/20259.54 EUR
9/9/20259.54 EUR
9/8/20259.54 EUR
9/5/20259.54 EUR
9/4/20259.54 EUR
9/3/20259.54 EUR
9/2/20259.54 EUR
9/1/20259.54 EUR
8/29/20259.54 EUR
8/28/20259.54 EUR
8/27/20259.54 EUR
8/26/20259.54 EUR
8/25/20259.54 EUR
8/22/20259.54 EUR
8/21/20259.54 EUR
8/20/20259.54 EUR
8/19/20259.54 EUR
8/18/20259.54 EUR
8/15/20259.54 EUR
8/14/20259.54 EUR
8/13/20259.54 EUR
8/12/20259.54 EUR
8/11/20259.54 EUR
8/8/20259.54 EUR
8/7/20259.54 EUR
Access this data via the Eulerpool API
Get Free API Key

Galapagos Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
239.72 M EUR
-88.26 M EUR
211.70 M EUR
Jan 1, 2024
275.65 M EUR
-188.34 M EUR
74.08 M EUR
Jan 1, 2025
1.11 B EUR
501.39 M EUR
320.88 M EUR
Jan 1, 2026 (e)
271.90 M EUR
-219.95 M EUR
-200.96 M EUR
Jan 1, 2027 (e)
162.44 M EUR
-223.17 M EUR
-257.68 M EUR
Jan 1, 2028 (e)
315.11 M EUR
-151.64 M EUR
-8.68 M EUR
Jan 1, 2029 (e)
297.05 M EUR
-92.32 M EUR
0.00 EUR
Jan 1, 2030 (e)
289.62 M EUR
-101.75 M EUR
0.00 EUR

Galapagos Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 6, 2026, 2:36 PM
 
REVENUEB EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
0.040.130.130.290.830.480.480.240.240.281.110.270.160.320.300.29
-43.48230.77-1.55126.77189.58-42.691.26-50.21-0.8315.06304.36-75.63-40.2294.44-5.71-2.69
-230.77-7.75-71.65-11.8149.64-9.4199.79100.00100.0087.2797.3097.3097.3097.3097.3097.30
-0.09-0.01-0.09-0.030.41-0.050.480.240.240.241.080.260.160.310.290.28
-89.00-11.00-89.00-44.00368.00-294.00-165.00-131.00-88.00-188.00501.00-219.00-223.00-151.00-92.00-101.00
-228.21-8.53-70.08-15.2844.12-61.51-34.09-54.36-36.82-68.3645.05-80.81-137.65-47.94-30.98-34.95
-118.0054.00-115.00-29.00149.00-305.00-125.00-217.00211.0074.00320.00-200.00-257.00-8.00––
-457.58-145.76-312.96-74.78-613.79-304.70-59.0273.60-197.24-64.93332.43-162.5028.50-96.89––
44.4348.3350.9754.6764.8765.9466.5565.8465.9066.0365.8965.8965.8965.8965.8965.89
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Galapagos generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Galapagos retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Galapagos's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Galapagos has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Galapagos's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Galapagos stock margins

The Galapagos margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Galapagos. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Galapagos.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
99.66 %
-34.15 %
-25.87 %
Jan 1, 2022
100.00 %
-54.32 %
-90.36 %
Jan 1, 2023
100.00 %
-36.82 %
88.31 %
Jan 1, 2024
87.35 %
-68.33 %
26.88 %
Jan 1, 2025
97.33 %
45.08 %
28.85 %
Jan 1, 2026 (e)
97.33 %
-80.90 %
-73.91 %
Jan 1, 2027 (e)
97.33 %
-137.38 %
-158.63 %
Jan 1, 2028 (e)
97.33 %
-48.12 %
-2.76 %

Galapagos Stock Revenue, EBIT, Earnings per Share

The Galapagos earnings per share therefore indicates how much revenue Galapagos has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
7.29 EUR
-2.49 EUR
-1.88 EUR
Jan 1, 2022
3.66 EUR
-1.99 EUR
-3.31 EUR
Jan 1, 2023
3.64 EUR
-1.34 EUR
3.21 EUR
Jan 1, 2024
4.17 EUR
-2.85 EUR
1.12 EUR
Jan 1, 2025
16.88 EUR
7.61 EUR
4.87 EUR
Jan 1, 2026 (e)
4.13 EUR
-3.34 EUR
-3.05 EUR
Jan 1, 2027 (e)
2.47 EUR
-3.39 EUR
-3.91 EUR
Jan 1, 2028 (e)
4.78 EUR
-2.30 EUR
-0.13 EUR

Galapagos business model & stock analysis

Galapagos NV is a Belgian biopharmaceutical company focused on the development of novel drugs, particularly for autoimmune diseases and fibrosis. The company was founded in 1999 by Onno van de Stolpe and is headquartered in Mechelen, Belgium.

Galapagos SWOT Analysis

Strengths

Galapagos NV possesses several strengths that contribute to its success in the market:

Galapagos NV invests significantly in research and development, enabling it to develop innovative and unique products.

The company offers a wide range of products and services, catering to various sectors and markets, reducing dependency on a single product or market segment.

Galapagos NV holds a robust portfolio of intellectual property rights, providing a competitive advantage and protection against potential infringements.

Weaknesses

Despite its strengths, Galapagos NV faces some weaknesses that can hinder its growth and performance:

The company operates in a highly competitive market and may struggle to gain significant market share in certain regions.

Galapagos NV heavily relies on collaborations and partnerships for funding and the commercialization of its products, which may limit control over decision-making processes.

Opportunities

Several opportunities exist for Galapagos NV to expand and improve its market position:

The increasing global demand for innovative biotechnology products presents a significant opportunity for Galapagos NV to expand its customer base.

The company can focus on targeting emerging markets, where there is a potential for rapid growth and less competition.

Threats

Galapagos NV faces several threats that could negatively impact its business:

The biotechnology industry is subject to strict regulations and evolving legal requirements, which could increase compliance costs and pose challenges to the company's operations.

Competitors in the biotechnology sector are continuously developing new products and technologies, intensifying competition and potentially reducing market share for Galapagos NV.

Galapagos Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Galapagos historical P/E ratio, EBIT multiple, and P/S ratio

Galapagos annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Galapagos shares outstanding

The number of shares of Galapagos was 65.89 M in 2025. This indicates how many shares Galapagos is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
66.55 M Stocks
Jan 1, 2022
65.84 M Stocks
Jan 1, 2023
65.90 M Stocks
Jan 1, 2024
66.03 M Stocks
Jan 1, 2025
65.89 M Stocks
Jan 1, 2026 (e)
65.89 M Stocks
Jan 1, 2027 (e)
65.89 M Stocks
Jan 1, 2028 (e)
65.89 M Stocks

Current Galapagos forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
3.63 %
Buy
16.67 % (3)
Hold
33.33 % (6)
Sell
50.00 % (9)
12M Price Target
28.46
Last Price
15.99
Currency
EUR
12M Return Potential
77.97 %
LTM Return
0 %

Galapagos Earnings Calls

2025

Galapagos Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
2/22/2024-3.70EUR-27.04 MEUR-2023 Q4
2/23/2023-0.41EUR-178.64 MEUR-2022 Q4
11/3/2022-0.82EUR-152.25 MEUR-2022 Q3
8/4/2022-0.83EUR-151.22 MEUR-2022 Q2
5/5/2022-1.08EUR-114.69 MEUR-2022 Q1
2/24/2022-0.65EUR-149.45 MEUR-2021 Q4
11/4/2021-1.33EUR-133.80 MEUR-2021 Q3
8/5/2021-0.89EUR-129.89 MEUR-2021 Q2
5/6/2021-0.56EUR-136.99 MEUR-2021 Q1
2/18/2021-0.96EUR-138.78 MEUR-2020 Q4

EESG©

Eulerpool ESG Scorecard© for the Galapagos stock

92/100
99
Environment
99
Social
77
Governance
E

Environment

20
Scope 1 - Direct Emissions2,922
Scope 2 - Indirect emissions from purchased energy1,132
Scope 3 - Indirect emissions within the value chain36,537
Total CO₂ emissions4,054
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees56
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Galapagos shareholder structure

% Name
2.41667%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.44943%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
0.88383%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
0.76765%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
0.39651%
Nuveen LLC
Nuveen LLC
0.26217%
BlackRock Advisors (UK) Limited
BlackRock Advisors (UK) Limited

Galapagos Beneficial Ownership Filings (SEC 13D/G)

Free Float
67.6%
Float Shares
-
Shares Outstanding
-

Galapagos Executives and Management Board

17 members · avg. age 59 · 47 % women

Management

HG

Mr. Henry Gosebruch

Chief Executive Officer, Executive Director · since 2025

–
AC

Mr. Aaron Cox (41)

Chief Financial Officer

–
AM

Ms. Annelies Missotten (53)

Chief Human Resources Officer, Executive Vice President, Member of the Management Board

–
VC

Ms. Valeria Cnossen (52)

Executive Vice President, General Counsel, Member of the Management Board

–
DG

Mr. Dan Grossman

Chief Strategy Officer

–
SK

Ms. Sooin Kwon

Chief Business Officer

–

Board of Directors

JC

Mr. Jerome Contamine (68)

Non-Executive Independent Chairman of the Board

183,440.00 EUR
ES

Ms. Elisabeth Svanberg (64)

Non-Executive Independent Director

161,688.00 EUR
SS

Mr. Simon Sturge (66)

Non-Executive Independent Director

132,402.00 EUR
SS

Dr. Susanne Schaffert (58)

Non-Executive Independent Director

122,572.00 EUR
PG

Mr. Peter Guenter (62)

Non-Executive Independent Director

121,688.00 EUR
AD

Mr. Andrew Dickinson (55)

Non-Executive Non-Independent Director

–

Galapagos Supply Chain

Galapagos Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
10 companies
#Nameβ 1YTrend
1
Oxurion
Supplier·Customer·Biotechnology·BE
0.21
0.92
0.13
-0.69
-0.20
0.62
—
2
Ryvu Therapeutics
Supplier·Customer·Life Sciences Tools & Services·PL
-0.03
0.77
0.22
-0.78
-0.58
0.45
—
#Nameβ 1YTrend
1
e-Therapeutics
Supplier·Biotechnology·GB
0.05
0.47
0.27
-0.83
-0.62
-0.73
—
2
Evotec
Supplier·Customer·Life Sciences Tools & Services·DE
-0.15
0.85
0.37
-0.84
-0.71
-0.72
—
3
AbbVie
Customer·Biotechnology·US
0.10
0.84
0.51
0.87
0.54
-0.57
0.32
4
Molecure
Supplier·Customer·Pharmaceuticals·PL
0.45
0.76
0.15
-0.70
-0.22
-0.56
—
5
Intervest Offices
Supplier·Equity Real Estate Investment Trusts (REITs)·BE
-0.23
0.19
0.49
-0.18
-0.05
-0.55
—

Frequently asked questions about Galapagos

The business model of Galapagos NV is centered around the discovery, development, and commercialization of innovative medicines. The company primarily focuses on the development of small molecule drugs that target specific proteins involved in various diseases. With a strong emphasis on research and development, Galapagos NV collaborates with partners in the pharmaceutical industry to bring novel therapies to patients. By leveraging its proprietary target discovery platform, the company identifies potential drug targets and advances them through preclinical and clinical development stages. Through strategic collaborations and licensing agreements, Galapagos NV aims to bring its pipeline of promising drug candidates to market, addressing unmet medical needs and contributing to improved patient outcomes.

Galapagos NV is primarily active in the biotechnology and pharmaceutical industries.

Galapagos NV faces competition from various pharmaceutical companies in the market. Some of the main competitors include companies like Novartis, Johnson & Johnson, Pfizer, and Roche. These companies operate in similar therapeutic areas and compete with Galapagos NV in developing innovative drug candidates and therapies. Galapagos NV strives to maintain a competitive edge by leveraging its distinctive scientific expertise, robust pipeline, and strategic collaborations.

Galapagos NV is a renowned biotechnology company headquartered in Mechelen, Belgium. Founded in 1999, Galapagos NV has established itself as a leader in drug discovery and development. The company focuses on the discovery and development of small molecule medicines with a specialization in inflammation, fibrosis, and other diseases. Galapagos NV has an excellent track record of successful collaborations with pharmaceutical giants such as Gilead Sciences. With a strong commitment to innovation and advancement, Galapagos NV continues to make significant contributions to the healthcare industry, bringing hope and potential for novel treatments to patients worldwide.

Galapagos NV, a renowned biotechnology company, has accomplished several notable milestones over the years. The company has made significant progress in developing innovative therapies for various diseases. It successfully advanced its lead drug candidate, Filgotinib, through multiple clinical trials, demonstrating promising results in treating rheumatoid arthritis, Crohn's disease, and other inflammatory conditions. Galapagos NV has also fostered strong partnerships with major pharmaceutical companies to further advance its research pipeline. Furthermore, the company received regulatory approvals for its products in various regions, solidifying its position as a pioneer in the biotech industry. Galapagos NV continues to drive innovation, striving to improve patients' lives through groundbreaking discoveries.

Galapagos NV primarily operates in several countries and regions. The company has a significant presence in Europe, specifically in Belgium and the Netherlands, where its headquarters are located. Galapagos also has operations and offices in France, Spain, Italy, Switzerland, and the United Kingdom. Furthermore, the company has expanded its footprint across the Atlantic, with a presence in the United States and Canada. With its global presence, Galapagos NV is able to leverage diverse markets and collaborations to further its research, development, and commercialization efforts.

Galapagos NV represents a commitment to innovation, collaboration, and scientific excellence. The company values diversity and fosters an entrepreneurial spirit within its teams. Galapagos NV's corporate philosophy revolves around a patient-centric approach, aiming to develop transformative medicines that improve the lives of patients. By leveraging cutting-edge technology and extensive research, the company strives to bring forth breakthrough therapies for various diseases. Galapagos NV's dedication to research and development, along with its emphasis on partnerships and scientific expertise, drives its mission to deliver innovative solutions to healthcare challenges.

Analysts currently set an average price target of 30.17 EUR for the Galapagos stock (median: 28.46 EUR), implying +88.7 % versus the latest price. The consensus is based on 18 analyst ratings.

Galapagos Analyst Price Targets 2026

18 analysts currently rate the Galapagos stock: 3 recommend buying, 6 holding and 9 selling. For 2026, analysts expect Galapagos to generate revenue of 271.90 M EUR and earnings per share of -3.05 EUR.

Galapagos Analyst Price Targets 2026

The Galapagos share (GLPG.AS) is listed on 10 stock exchanges, including: XETRA (GXE.DE), Frankfurt (GXE.F), München (GXE.MU), Düsseldorf (GXE.DU), London (0JXZ.L), Wien (GLPG.VI), Amsterdam (GLPG.AS).

Galapagos NV is a biotechnology company specialized in the discovery and development of new drugs for a variety of diseases. Its business model is based on a three-step strategy: Target Discovery, Drug Development, and Clinical Candidate Development. The company uses proprietary technologies, including AI methods and big data analysis, to identify promising target molecules and develop potential drugs. These drugs are then tested for efficacy and safety in clinical studies, with the goal of bringing new treatments to market faster and more efficiently. Galapagos also collaborates with other companies and organizations to develop innovative treatment options, such as their partnership with Gilead Sciences for the development of drugs for Idiopathic Pulmonary Fibrosis. Overall, Galapagos strives to advance the discovery and development of drugs for various diseases through the use of innovative technologies and collaboration with experts in the field.

The expected revenue of Galapagos is 271.90 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Galapagos is -200.96 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Galapagos is currently -7.32. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Galapagos stock.

The price-to-sales ratio (P/S) of Galapagos is currently 5.41. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Galapagos stock.

The Eulerpool Quality Score for Galapagos is 5/10.

The ISIN of Galapagos is BE0003818359. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Galapagos is A0EAT9. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Galapagos is GLPG.AS. The ticker symbol is used to trade Galapagos shares on the stock exchange.

Galapagos paid dividends every year for the past 0 years.

Galapagos is assigned to the 'Health' sector.

The dividends of Galapagos are distributed in EUR.

All fundamentals and in-depth analysis of Galapagos

Our stock analysis for Galapagos stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Galapagos. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Galapagos Stock
Galapagos Revenue→
Galapagos Stock
Galapagos Net Income→
Galapagos Stock
Galapagos P/E→
Galapagos Stock
Galapagos P/S→
Galapagos Stock
Galapagos EBIT→
Galapagos Stock
Galapagos Dividend→
Galapagos Stock
Galapagos Directors Dealings→
Galapagos Stock
Galapagos Stocks→
Galapagos Stock
Galapagos Market capitalization→
Galapagos Stock
Galapagos Debt→
Galapagos Stock
Galapagos Liabilities→
Galapagos Stock
Galapagos Equity→
Galapagos Stock
Galapagos AAQS→
Galapagos Stock
Galapagos Employees→
Galapagos Stock
Galapagos ROE→
Galapagos Stock
Galapagos ROA→
Galapagos Stock
Galapagos ROCE→
Galapagos Stock
Galapagos News→
Galapagos Stock
Galapagos Analyst Price Targets→

Health Stocks

Galectin TherapeuticsGabatherGalectoG3 Global BhdGalenicaG Medical Innovations HoldingsGalera TherapeuticsFutureChem CoGalmed PharmaceuticalsFuture Care Trading Compnay SJSCGamerica Holdings and AcquisitionsFutura MedicalAll Stocks A–Z →